MY169750A - Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate - Google Patents

Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate

Info

Publication number
MY169750A
MY169750A MYPI2014701375A MYPI2014701375A MY169750A MY 169750 A MY169750 A MY 169750A MY PI2014701375 A MYPI2014701375 A MY PI2014701375A MY PI2014701375 A MYPI2014701375 A MY PI2014701375A MY 169750 A MY169750 A MY 169750A
Authority
MY
Malaysia
Prior art keywords
tablet
dihydroquinoline
difluoromethoxy
cyclopropyl
dihydro
Prior art date
Application number
MYPI2014701375A
Other languages
English (en)
Inventor
Kakuda Sahoe
Miyazaki Tsutomu
Okada Kotaro
Original Assignee
Fujifilm Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co Ltd filed Critical Fujifilm Toyama Chemical Co Ltd
Publication of MY169750A publication Critical patent/MY169750A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
MYPI2014701375A 2011-11-30 2012-11-29 Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate MY169750A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011261727 2011-11-30

Publications (1)

Publication Number Publication Date
MY169750A true MY169750A (en) 2019-05-15

Family

ID=48535494

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014701375A MY169750A (en) 2011-11-30 2012-11-29 Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate

Country Status (10)

Country Link
JP (1) JP6117112B2 (ja)
CN (2) CN104039322A (ja)
BR (1) BR112014012994A2 (ja)
MX (1) MX350659B (ja)
MY (1) MY169750A (ja)
PH (1) PH12014501224A1 (ja)
RU (1) RU2633477C2 (ja)
SG (1) SG11201402597WA (ja)
WO (1) WO2013081044A1 (ja)
ZA (1) ZA201403942B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017073738A1 (ja) * 2015-10-29 2017-05-04 日本臓器製薬株式会社 フェキソフェナジンを有効成分とする錠剤
TWI727036B (zh) * 2016-04-27 2021-05-11 日商富山化學工業股份有限公司 包含甲苯磺酸托氟沙星、崩解劑及酸性胺基酸之錠劑
JP7058104B2 (ja) * 2017-10-19 2022-04-21 日本化薬株式会社 アプレピタントを有効成分とする医薬錠剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639458A (en) * 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
EE04418B1 (et) * 1998-11-10 2005-02-15 Bayer Aktiengesellschaft Moksifloksatsiini farmatseutiline preparaat
JP4370050B2 (ja) * 2000-12-04 2009-11-25 大正製薬株式会社 クラリスロマイシン錠剤およびその製造法
ATE382338T1 (de) * 2003-03-19 2008-01-15 Jordanian Pharmaceutical Mfg Nicht-hygroskopische pharmazeutische zusammensetzungen die nicht hydratisierte quinolon-carbonsäure enthalten
JP4702763B2 (ja) * 2003-07-30 2011-06-15 塩野義製薬株式会社 結晶セルロースを含有する安定な錠剤
CA2576589C (en) * 2004-08-13 2013-11-12 Schering-Plough Ltd. Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
FI20080352A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi korkean lääkepitoisuuden tabletin valmistamiseksi
FI20080353A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi erittäin korkean lääkepitoisuuden tabletin valmistamiseksi
JP2011068647A (ja) * 2009-08-31 2011-04-07 Kowa Co アスパラギン酸又はその塩含有固形製剤
WO2011059075A1 (ja) * 2009-11-13 2011-05-19 味の素株式会社 グルタミン酸およびアルギニンの高含有製剤

Also Published As

Publication number Publication date
ZA201403942B (en) 2015-08-26
CN104039322A (zh) 2014-09-10
WO2013081044A1 (ja) 2013-06-06
SG11201402597WA (en) 2014-09-26
CN109662952A (zh) 2019-04-23
BR112014012994A2 (pt) 2017-06-13
MX2014006378A (es) 2014-10-13
PH12014501224B1 (en) 2014-09-08
RU2014126094A (ru) 2016-01-27
PH12014501224A1 (en) 2014-09-08
MX350659B (es) 2017-09-13
JPWO2013081044A1 (ja) 2015-04-27
RU2633477C2 (ru) 2017-10-12
JP6117112B2 (ja) 2017-04-19

Similar Documents

Publication Publication Date Title
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
PH12015500587A1 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
PH12015500460B1 (en) Coated pharmaceutical composition containing regorafenib
GEP20217235B (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
PH12016501328A1 (en) Pharmaceutical composition containing pyridylaminoacetic acid compound
MY169750A (en) Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
PH12014502407B1 (en) New alfentanil composition for the treatment of acute pain
PH12017500536A1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
MX2015015681A (es) Composicion farmaceutica que comprende fingolimod.
MX343986B (es) Composiciones farmaceuticas estabilizadas que comprenden sales de rasagilina.
TH153154A (th) ยาเม็ดซึ่งมี 1-ไซโคลโพรพิล-8-(ไดฟลูออโรเมธอกซี)-7-[(1r)-1-เมธิล-2,3-ไดไฮโดร-1h-ไอโซอินโดล-5-อิล]-4-ออกโซ-1,4-ไดไฮโดรควิโนลีน-3-คาร์บอกซิลิคแอซิดมีเธนซัลโฟนิคแอซิดไฮเดรท
CA2865484A1 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
TN2013000515A1 (en) Notch pathway signaling inhibitor compound
GR1007907B (el) Φαρμακευτικο σκευασμα περιεχον ενα φαινοκαρβαμικο αναστολεα της ακετυλχοληνεστερασης
MX2012014342A (es) Preparacion de una sal de levalbuterol.